Back to top
more

Harvard Bioscience (HBIO)

(Delayed Data from NSDQ)

$3.62 USD

3.62
55,311

+0.06 (1.69%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $3.63 +0.01 (0.28%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (33 out of 252)

Industry: Instruments - Scientific

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for HBIO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Harvard Bioscience, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 4 5 8 8 8
Receivables 16 17 22 18 21
Notes Receivable 0 0 0 0 0
Inventories 25 26 28 22 22
Other Current Assets 4 3 4 3 2
Total Current Assets 49 51 62 52 54
Net Property & Equipment 4 3 3 4 5
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 73 77 85 92 96
Deposits & Other Assets 6 8 5 1 2
Total Assets 137 145 162 156 165
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 6 6 5 6 5
Current Portion Long-Term Debt 6 4 3 2 7
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 1
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 14 11 15 11 10
Total Current Liabilities 27 23 25 21 25
Mortgages 0 0 0 0 0
Deferred Taxes/Income 1 1 2 2 2
Convertible Debt 0 0 0 0 0
Long-Term Debt 31 43 45 46 47
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1 1 0 3 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 64 73 79 80 83
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 232 229 226 232 229
Retained Earnings -146 -142 -133 -132 -125
Other Equity -14 -15 -10 -13 -13
Treasury Stock 0 0 0 11 11
Total Shareholder's Equity 73 72 83 77 82
Total Liabilities & Shareholder's Equity 137 145 162 156 165
Total Common Equity 73 72 83 77 82
Shares Outstanding 42.60 41.60 40.80 38.90 38.00
Book Value Per Share 1.72 1.74 2.04 1.97 2.15

Fiscal Year End for Harvard Bioscience, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 4 5 4 4
Receivables NA 16 15 17 18
Notes Receivable NA 0 0 0 0
Inventories NA 25 26 26 27
Other Current Assets NA 4 4 5 4
Total Current Assets NA 49 50 53 52
Net Property & Equipment NA 4 3 3 3
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 73 73 75 76
Deposits & Other Assets NA 6 8 6 8
Total Assets NA 137 140 143 146
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 6 6 5 6
Current Portion Long-Term Debt NA 6 3 3 3
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 14 12 13 12
Total Current Liabilities NA 27 24 23 23
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 1 1 1 1
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 31 35 38 41
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 1 1 1
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 64 65 68 71
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 232 233 232 230
Retained Earnings NA -146 -144 -143 -142
Other Equity NA -14 -15 -14 -15
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 73 74 75 74
Total Liabilities & Shareholder's Equity NA 137 140 143 146
Total Common Equity 0 73 74 75 74
Shares Outstanding 43.40 42.60 42.60 42.10 42.10
Book Value Per Share 0.00 1.72 1.74 1.79 1.77